118 related articles for article (PubMed ID: 33599758)
1. BiTtEn by Src inhibitors.
Rousselot P
Blood; 2021 Feb; 137(7):867-868. PubMed ID: 33599758
[No Abstract] [Full Text] [Related]
2. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
3. Recent progress of Src SH2 and SH3 inhibitors as anticancer agents.
Lu XL; Cao X; Liu XY; Jiao BH
Curr Med Chem; 2010; 17(12):1117-24. PubMed ID: 20158477
[TBL] [Abstract][Full Text] [Related]
4. Src kinases as targets for B cell acute lymphoblastic leukaemia therapy.
Li S
Expert Opin Ther Targets; 2005 Apr; 9(2):329-41. PubMed ID: 15934919
[TBL] [Abstract][Full Text] [Related]
5. Src inhibitors in breast cancer therapy.
Hiscox S; Nicholson RI
Expert Opin Ther Targets; 2008 Jun; 12(6):757-67. PubMed ID: 18479222
[TBL] [Abstract][Full Text] [Related]
6. Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.
Boschelli DH; Wang D; Wang Y; Wu B; Honores EE; Barrios Sosa AC; Chaudhary I; Golas J; Lucas J; Boschelli F
Bioorg Med Chem Lett; 2010 May; 20(9):2924-7. PubMed ID: 20363128
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of new 6-substituted-5-benzyloxy-4-oxo-4H-pyran-2-carboxamides as potential Src inhibitors.
Farard J; Lanceart G; Logé C; Nourrisson MR; Cruzalegui F; Pfeiffer B; Duflos M
J Enzyme Inhib Med Chem; 2008 Oct; 23(5):629-40. PubMed ID: 18686137
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
Krupkova L; Mojzikova R; Novotny J; Gazdova J; Divoka M; Skoumalova I; Rohon P; Jarosova M; Indrak K; Faber E; Divoky V
Int J Lab Hematol; 2015 Feb; 37(1):e11-5. PubMed ID: 24845482
[No Abstract] [Full Text] [Related]
9. An Antitumor 2-Hydroxyarylidene-4-cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor: Interaction Between TX-1123 Derivatives and Src Kinase.
Ohkura K; Kawaguchi Y; Tatematsu Y; Uto Y; Hori H
Anticancer Res; 2016 Jul; 36(7):3645-9. PubMed ID: 27354635
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
[TBL] [Abstract][Full Text] [Related]
11. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
12. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives.
Chand K; Prasad S; Tiwari RK; Shirazi AN; Kumar S; Parang K; Sharma SK
Bioorg Chem; 2014 Apr; 53():75-82. PubMed ID: 24632506
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of targeted interference with Src-mediated signal transduction events.
Ly QP; Yeatman TJ
Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
[No Abstract] [Full Text] [Related]
15. Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Wang Y; Shakespeare WC; Huang WS; Sundaramoorthi R; Lentini S; Das S; Liu S; Banda G; Wen D; Zhu X; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Dalgarno D; Clackson T; Sawyer TK
Bioorg Med Chem Lett; 2008 Sep; 18(17):4907-12. PubMed ID: 18691885
[TBL] [Abstract][Full Text] [Related]
16. 4-Aryl-4H-chromene-3-carbonitrile derivatives: evaluation of Src kinase inhibitory and anticancer activities.
Fallah-Tafti A; Tiwari R; Shirazi AN; Akbarzadeh T; Mandal D; Shafiee A; Parang K; Foroumadi A
Med Chem; 2011 Sep; 7(5):466-72. PubMed ID: 21801146
[TBL] [Abstract][Full Text] [Related]
17. Effectively targeting CRAF: rational serendipity targeting SRC?
Flaherty KT
Pigment Cell Melanoma Res; 2015 May; 28(3):242-3. PubMed ID: 25677495
[No Abstract] [Full Text] [Related]
18. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
Stanley A; Ashrafi GH; Seddon AM; Modjtahedi H
Sci Rep; 2017 Jun; 7(1):3964. PubMed ID: 28638122
[TBL] [Abstract][Full Text] [Related]
20. SRC kinase inhibitors: an update on patented compounds.
Schenone S; Brullo C; Musumeci F; Radi M; Castagnolo D
Curr Med Chem; 2011; 18(33):5061-78. PubMed ID: 22050754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
